4 completed, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow plitidepsin: new trials by email Literature Review of plitidepsin trials Research Report on plitidepsin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study in a Cohort of Adult Patients With COVID-19 Infection Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day - COVID-19 Infection | Phase 1 / Phase 2 | Completed | PharmaMar | 34 | 2022-01-25 | 2024-12-31 |
| Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19 Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day - COVID-19 | Phase 1 | Completed | PharmaMar | 46 | 2020-05-12 | 2022-08-23 |
| Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Plitidepsin, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | PharmaMar | 39 | 2014-06-01 | 2020-10-12 |
| Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas Plitidepsin and Sorafenib, Gemcitabine and Plitidepsin - Advanced Solid Tumors, Lymphomas | Phase 1 | Completed | PharmaMar | 45 | 2008-12-01 | 2011-06-07 |
| Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia Plitidepsin plus Cytarabine - Relapsed/Refractory Leukemia | Phase 1 / Phase 2 | Terminated | PharmaMar | 3 | 2007-11-01 | 2018-11-09 |
COVID-19 (2) · Neoplasms (2) · Coronavirus Infections (1) · Leukemia (1) · Lymphoma (1) · Multiple Myeloma (1)
PharmaMar (5)
Spain (3) · France (2) · United States (2)
Jean Charles Soria, MD (1) · Mark N. Stein, MD (1) · Mecide Gharibo, M.D. (1) · Pablo Guisado-Vasco, MD (1) · Pedro Landete, MD (1) · Roger Paredes, MD (1) · Vicente Estrada, MD (1)